Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, addressing the needs of the innovative drug industry in China, which has rapidly developed into the second-largest pharmaceutical market globally and is now in the second tier of global drug research and development. Group 1: Highlights of the New Regulations - Highlight 1: "Data Protection" Expanded to New Chemical Entities - The new regulations extend data protection to drugs containing new chemical entities, providing a protection period of up to 6 years for undisclosed trial data, encouraging drug innovation while balancing the relationship between innovative and generic drugs [5][4]. - Highlight 2: Institutionalization of the "Market Exclusivity" System - The new regulations establish a formal market exclusivity system for innovative drugs, granting up to 2 years of exclusivity for new pediatric drugs and up to 7 years for rare disease treatments, thus providing administrative protection for innovation [6][7]. - Highlight 3: Conditional Opening of Drug Contracted Segment Production - The regulations clarify conditions under which segmented production can be contracted, allowing for more flexibility in drug manufacturing while addressing potential risks associated with quality management and regulatory compliance [8][10]. - Highlight 4: Strengthening Oversight of Overseas New Drug Batch Approvals - The regulations enhance the management of commercial-scale batches of drugs approved overseas, allowing them to be sold in China after passing GMP compliance checks, thereby ensuring drug safety while meeting urgent clinical needs [11][10].

Core Viewpoint - The National Medical Products Administration (NMPA) is actively promoting the formulation of the "Implementation Measures for the Protection of Drug Trial Data," responding to the needs of the innovative drug industry and enhancing the regulatory framework to support drug development in China [1] Group 1: Drug Trial Data Protection - The revised "Regulations" expand the scope of drug trial data protection to include drugs with new chemical entities, providing a protection period of up to 6 years for undisclosed trial data [2] - The NMPA has previously solicited public opinions on the "Implementation Measures for the Protection of Drug Trial Data," indicating a move towards more concrete regulations [2] Group 2: Market Exclusivity Period - The new "Regulations" establish a market exclusivity period for innovative drugs, which had previously been discussed only in draft forms [3] - For new pediatric drugs and rare disease treatments, the exclusivity period can be up to 2 years and 7 years respectively, incentivizing the development of these critical medications [4] Group 3: Conditional Release of Drug Contracted Segment Production - The "Regulations" clarify conditions under which contracted segment production can be permitted, particularly for innovative drugs with special production requirements [6][7] - The segment production model has shown potential in reducing costs while maintaining efficacy, as evidenced by the successful registration of a rare disease treatment [6] Group 4: Strengthened Oversight of Imported Drug Batches - The "Regulations" enhance the oversight of commercial-scale batches of drugs approved for import before market approval, allowing for their sale under strict compliance with Good Manufacturing Practice (GMP) [8] - This approach aims to balance drug safety with the urgent clinical needs of patients, particularly for new drugs and treatments for rare diseases [8]

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" will take effect on May 15, 2026, optimizing the entire drug regulatory system and particularly enhancing the management of traditional Chinese medicine, pediatric drugs, and rare disease medications [1] Group 1: Drug Approval Process - The new regulations institutionalize and legalize the accelerated approval channels for breakthrough therapies, conditional approvals, priority reviews, and special approvals, which were first introduced in the 2020 "Drug Registration Management Measures" [2] - As of December 2025, 395 drug varieties have entered the breakthrough therapy program, 158 have received conditional approval, and 508 have entered the priority review channel, with the average review time for innovative drugs reduced by 25% compared to 2018 [2] - The clarity of the regulatory framework is expected to provide multinational companies with stable policy expectations, encouraging them to increase their investment in China and potentially lead global R&D projects from China [2] Group 2: Market Exclusivity - The new regulations introduce a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, provided that the drug supply is guaranteed [3] - This exclusivity is seen as a reasonable compensation for high-risk investments, which may attract more social capital into underdeveloped but essential areas [3] - The regulations support clinical value-oriented R&D and clarify the fast-track approval process for new drugs, aiming to expedite the availability of effective medications to patients [3] Group 3: Industry Transformation - The revisions are expected to trigger profound changes in China's pharmaceutical industry, pushing domestic companies to transition from low-level fast-follow strategies to high-level original innovation [5] - The competitive landscape is anticipated to shift from local market competition to global market competition, as companies adapt to the new regulatory environment [5] - The new regulations create a comprehensive innovation incentive ecosystem covering the entire drug lifecycle, which is particularly valuable in the context of ongoing challenges in healthcare negotiations and capital markets [4]

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" introduces significant innovations, particularly in supporting pediatric and rare disease medications through market exclusivity periods, which is expected to stimulate investment in these areas by companies like Yiling Pharmaceutical [2][7]. Group 1: Drug Innovation and Market Exclusivity - The new regulations provide a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, contingent on the commitment to ensure drug supply [2]. - Yiling Pharmaceutical emphasizes innovation as a core driver of its development, establishing a research model based on clinical practice and traditional Chinese medicine theories [2][3]. - The company has 17 patented traditional Chinese medicine products on the market, with 12 included in the National Basic Medical Insurance Directory and 5 in the National Essential Medicines List [3]. Group 2: Research and Development Focus - Yiling Pharmaceutical plans to increase investment in pediatric and rare disease drug development following the implementation of the new regulations, with products like "Children's Lianhua Qingwen Granules" already in the application stage [3]. - The company has submitted new drug applications for several innovative traditional Chinese medicines and has five others in Phase II clinical trials [3]. Group 3: Quality Control and Safety - The new regulations impose stricter requirements on the production and sale of traditional Chinese medicine, necessitating improved quality control systems from source to end [4][6]. - Yiling Pharmaceutical has established a comprehensive quality management system based on Good Manufacturing Practice (GMP), focusing on full lifecycle quality control [5][6]. - The company has created 60 standardized traditional Chinese medicine cultivation bases across the country to ensure the quality and efficacy of its products [6]. Group 4: Future Directions - Yiling Pharmaceutical aims to enhance innovation investment, improve quality systems, promote internationalization, and strengthen talent development in response to the new regulations [7].

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law" represents the first comprehensive update in 23 years, with over 90% of its provisions modified, focusing on encouraging new drug research and innovation, enhancing market exclusivity, data protection, and segmented production [3][4][5]. Encouragement of New Drug Research and Innovation - A significant focus of the revised regulations is the encouragement of new drug research and innovation, including the establishment of accelerated drug registration processes and market exclusivity for pediatric and rare disease medications [4][5]. - Article 15 of the revised regulations outlines four accelerated approval procedures for eligible drug applications, enhancing the legal basis for administrative efficiency in drug review processes [5][6]. - Market exclusivity provisions include up to 2 years for pediatric drugs and up to 7 years for rare disease drugs, addressing the gap in available treatments and the challenges in clinical trials for these categories [5][6]. Data Protection and Patent Linkage - The revised regulations include provisions for data protection for drugs with new chemical entities, allowing for the protection of undisclosed clinical trial data for various scenarios, including innovative and modified new drugs [7]. - Although "patent term compensation" and "patent linkage" were not included in the revised regulations, existing laws and mechanisms already address these aspects [8]. Benefits for Innovative Pharmaceutical Companies - The comprehensive upgrade of the regulations is expected to provide substantial benefits for innovative pharmaceutical companies, particularly those focused on pediatric and rare disease drugs, as well as first-in-class (FIC) drugs [11]. - The regulations are anticipated to attract capital towards high-efficiency, high-value research-oriented companies, acting as a catalyst for the recovery of the capital market [11]. - Companies are encouraged to focus on unmet clinical needs, particularly in rare diseases and oncology, while also enhancing early commercialization strategies and lifecycle management capabilities [11].

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law" encourages new drug research and innovation, strengthens market exclusivity, data protection, and segmented production, which are key concerns for companies and the industry [1][2]. Encouragement of New Drug Research and Innovation - A major focus of the revised regulations is to encourage new drug research and innovation, including the establishment of accelerated drug registration procedures, market exclusivity for pediatric and rare disease drugs, and data protection for drugs with new chemical entities [1][2]. - Article 15 of the revised regulations mentions that eligible drug registration applications can adopt breakthrough therapy procedures, conditional approval procedures, priority review and approval procedures, and special approval procedures to accelerate drug market entry [2]. Market Exclusivity and Data Protection - Article 21 states that eligible pediatric drugs can receive a market exclusivity period of up to 2 years, while rare disease drugs can receive up to 7 years [2][3]. - Article 22 specifies that data protection for drugs with new chemical entities can last up to 6 years from the date of drug registration, covering various scenarios including innovative drugs and improved new drugs that have not been marketed domestically [3]. Impact on Drug Production and Industry Guidance - The revised regulations provide top-level, principle-based guidance for industry promotion, allowing drug marketing authorization holders to delegate segmented production to qualified manufacturers [5]. - Article 36 allows for the sale of drugs that meet release requirements after obtaining drug approval documents, which can reduce waste and environmental burdens during the commercialization phase [5]. Financing and Investment Opportunities - The systematic upgrade of the regulations may create substantial benefits for drug company financing by clarifying the lifecycle responsibilities of drug marketing authorization holders and optimizing the separation of holding and production mechanisms [6]. - The regulations are expected to attract capital towards high-efficiency, high-value research-oriented drug companies, with a particular focus on pediatric drugs, rare diseases, and first-in-class (FIC) innovative drugs [6].

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" aims to promote drug innovation and clinical value-oriented drug development, effective from May 15, 2026 [1][2][4] Group 1: Drug Development and Innovation - The regulations support the development and innovation of drugs based on clinical value, encouraging the research and creation of new drugs [1][2] - It establishes a fast-track registration process for drug listings and clarifies the re-registration procedures [1][3] - The regulations provide market exclusivity for eligible pediatric and rare disease medications, aligning with international practices to ensure equitable access to health [2][3] Group 2: Drug Production and Management - The regulations emphasize strengthening drug production management and clarify the responsibilities of drug marketing authorization holders [1][3] - It specifies management requirements for traditional Chinese medicine products and outlines the conditions under which drug production can be entrusted [1][3] Group 3: Clinical Trial and Data Protection - The regulations introduce a modernized drug review and approval system focused on clinical value, facilitating faster market access for innovative drugs [3][4] - It includes provisions for data protection related to drug trials, balancing the interests of innovation and generic competition [3][4] - The data protection system is designed to enhance confidence in drug innovation while allowing for simplified applications for generics after the protection period [3] Group 4: Future Implications - The implementation of these regulations is expected to improve the quality and efficiency of drug review and approval processes, ultimately benefiting public health and advancing China from a major pharmaceutical country to a strong pharmaceutical nation [4]